Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy

Scott L. Charland, Daniel C Malone

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Epidemiological data suggests for every 1 reduction in LDL-C there is a corresponding 11.5 reduction in cardiovascular events (CVEs). Additionally, for every 23 increase in HDL-C there is a reduction in CVEs by 24 that is independent of LDL-C. With numerous treatment options for managing dyslipidemia, it is important to evaluate agents that result in the greatest reduction of CVEs. Objective: To compare current high-potency dyslipidemia pharmacotherapy with respect to changes in LDL-C and HDL-C and estimate risk reductions for CVEs. Methods: This study is an analysis of existing published studies for dyslipidemia products marketed in the US. Literature searches were conducted using Medline, International Pharmaceutical Abstracts, Embase, and CINAH to identify trials for niacin extended-release and lovastatin (NER/L); niacin extended-release and simvastatin (NER/S); rosuvastatin (R); and, ezetimibe/simvastatin (E/S) from database inception to 1 May 2009. Demographics and changes from baseline in LDL-C and HDL-C were abstracted and HDL-C to LDL-C change (Δ-lipids) was created for each therapy. Using a previously validated model the percent reduction in CVEs was estimated for each treatment strategy. Results: Data for 177 treatment arms (120 unique reports), accounting for drug and dose were abstracted. The range in mean±SD% Δ-lipids depending on drug dose was: E/S, 58±6 to 67±3; R, 51±5 to 65±5; NER/L, 33±7 to 75±7; and NER/S, 48 to 77±4. Risk reductions were greatest for NER/statin combinations, with percent risk reductions greater than 77 for NER/S, 2000mg/10mg and 83 NER/S, 2000mg/40mg. Ignoring medication strengths, reductions in CVEs ranged from 58 for R, 60 for E/S, 61 for NER/L, and 72 for NER/S. Limitations: There are several potential limitations associated with this study including: publication bias, English only search, limited published studies with NER in combination with L or S, adherent populations, and aggregation of multiple populations. Conclusion: The results of the analysis suggest that greater risk reductions in CVEs occur with combination therapies, especially those including niacin extended-release (NER). Up to an 83 risk reduction was estimated for the highest doses of NER and simvastatin (NER/S).

Original languageEnglish (US)
Pages (from-to)365-375
Number of pages11
JournalCurrent Medical Research and Opinion
Volume26
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Niacin
Risk Reduction Behavior
Dyslipidemias
Lipids
Simvastatin
Lovastatin
Therapeutics
Pharmaceutical Preparations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Publication Bias
Population
Demography
Databases

Keywords

  • Cardiovascular events
  • Cholesterol
  • Dyslipidemia
  • Lipid-lowering therapy
  • Lipids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. / Charland, Scott L.; Malone, Daniel C.

In: Current Medical Research and Opinion, Vol. 26, No. 2, 02.2010, p. 365-375.

Research output: Contribution to journalArticle

@article{ec170165c22f4540bfc468f1a9d36ab5,
title = "Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy",
abstract = "Background: Epidemiological data suggests for every 1 reduction in LDL-C there is a corresponding 11.5 reduction in cardiovascular events (CVEs). Additionally, for every 23 increase in HDL-C there is a reduction in CVEs by 24 that is independent of LDL-C. With numerous treatment options for managing dyslipidemia, it is important to evaluate agents that result in the greatest reduction of CVEs. Objective: To compare current high-potency dyslipidemia pharmacotherapy with respect to changes in LDL-C and HDL-C and estimate risk reductions for CVEs. Methods: This study is an analysis of existing published studies for dyslipidemia products marketed in the US. Literature searches were conducted using Medline, International Pharmaceutical Abstracts, Embase, and CINAH to identify trials for niacin extended-release and lovastatin (NER/L); niacin extended-release and simvastatin (NER/S); rosuvastatin (R); and, ezetimibe/simvastatin (E/S) from database inception to 1 May 2009. Demographics and changes from baseline in LDL-C and HDL-C were abstracted and HDL-C to LDL-C change (Δ-lipids) was created for each therapy. Using a previously validated model the percent reduction in CVEs was estimated for each treatment strategy. Results: Data for 177 treatment arms (120 unique reports), accounting for drug and dose were abstracted. The range in mean±SD{\%} Δ-lipids depending on drug dose was: E/S, 58±6 to 67±3; R, 51±5 to 65±5; NER/L, 33±7 to 75±7; and NER/S, 48 to 77±4. Risk reductions were greatest for NER/statin combinations, with percent risk reductions greater than 77 for NER/S, 2000mg/10mg and 83 NER/S, 2000mg/40mg. Ignoring medication strengths, reductions in CVEs ranged from 58 for R, 60 for E/S, 61 for NER/L, and 72 for NER/S. Limitations: There are several potential limitations associated with this study including: publication bias, English only search, limited published studies with NER in combination with L or S, adherent populations, and aggregation of multiple populations. Conclusion: The results of the analysis suggest that greater risk reductions in CVEs occur with combination therapies, especially those including niacin extended-release (NER). Up to an 83 risk reduction was estimated for the highest doses of NER and simvastatin (NER/S).",
keywords = "Cardiovascular events, Cholesterol, Dyslipidemia, Lipid-lowering therapy, Lipids",
author = "Charland, {Scott L.} and Malone, {Daniel C}",
year = "2010",
month = "2",
doi = "10.1185/03007990903484802",
language = "English (US)",
volume = "26",
pages = "365--375",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy

AU - Charland, Scott L.

AU - Malone, Daniel C

PY - 2010/2

Y1 - 2010/2

N2 - Background: Epidemiological data suggests for every 1 reduction in LDL-C there is a corresponding 11.5 reduction in cardiovascular events (CVEs). Additionally, for every 23 increase in HDL-C there is a reduction in CVEs by 24 that is independent of LDL-C. With numerous treatment options for managing dyslipidemia, it is important to evaluate agents that result in the greatest reduction of CVEs. Objective: To compare current high-potency dyslipidemia pharmacotherapy with respect to changes in LDL-C and HDL-C and estimate risk reductions for CVEs. Methods: This study is an analysis of existing published studies for dyslipidemia products marketed in the US. Literature searches were conducted using Medline, International Pharmaceutical Abstracts, Embase, and CINAH to identify trials for niacin extended-release and lovastatin (NER/L); niacin extended-release and simvastatin (NER/S); rosuvastatin (R); and, ezetimibe/simvastatin (E/S) from database inception to 1 May 2009. Demographics and changes from baseline in LDL-C and HDL-C were abstracted and HDL-C to LDL-C change (Δ-lipids) was created for each therapy. Using a previously validated model the percent reduction in CVEs was estimated for each treatment strategy. Results: Data for 177 treatment arms (120 unique reports), accounting for drug and dose were abstracted. The range in mean±SD% Δ-lipids depending on drug dose was: E/S, 58±6 to 67±3; R, 51±5 to 65±5; NER/L, 33±7 to 75±7; and NER/S, 48 to 77±4. Risk reductions were greatest for NER/statin combinations, with percent risk reductions greater than 77 for NER/S, 2000mg/10mg and 83 NER/S, 2000mg/40mg. Ignoring medication strengths, reductions in CVEs ranged from 58 for R, 60 for E/S, 61 for NER/L, and 72 for NER/S. Limitations: There are several potential limitations associated with this study including: publication bias, English only search, limited published studies with NER in combination with L or S, adherent populations, and aggregation of multiple populations. Conclusion: The results of the analysis suggest that greater risk reductions in CVEs occur with combination therapies, especially those including niacin extended-release (NER). Up to an 83 risk reduction was estimated for the highest doses of NER and simvastatin (NER/S).

AB - Background: Epidemiological data suggests for every 1 reduction in LDL-C there is a corresponding 11.5 reduction in cardiovascular events (CVEs). Additionally, for every 23 increase in HDL-C there is a reduction in CVEs by 24 that is independent of LDL-C. With numerous treatment options for managing dyslipidemia, it is important to evaluate agents that result in the greatest reduction of CVEs. Objective: To compare current high-potency dyslipidemia pharmacotherapy with respect to changes in LDL-C and HDL-C and estimate risk reductions for CVEs. Methods: This study is an analysis of existing published studies for dyslipidemia products marketed in the US. Literature searches were conducted using Medline, International Pharmaceutical Abstracts, Embase, and CINAH to identify trials for niacin extended-release and lovastatin (NER/L); niacin extended-release and simvastatin (NER/S); rosuvastatin (R); and, ezetimibe/simvastatin (E/S) from database inception to 1 May 2009. Demographics and changes from baseline in LDL-C and HDL-C were abstracted and HDL-C to LDL-C change (Δ-lipids) was created for each therapy. Using a previously validated model the percent reduction in CVEs was estimated for each treatment strategy. Results: Data for 177 treatment arms (120 unique reports), accounting for drug and dose were abstracted. The range in mean±SD% Δ-lipids depending on drug dose was: E/S, 58±6 to 67±3; R, 51±5 to 65±5; NER/L, 33±7 to 75±7; and NER/S, 48 to 77±4. Risk reductions were greatest for NER/statin combinations, with percent risk reductions greater than 77 for NER/S, 2000mg/10mg and 83 NER/S, 2000mg/40mg. Ignoring medication strengths, reductions in CVEs ranged from 58 for R, 60 for E/S, 61 for NER/L, and 72 for NER/S. Limitations: There are several potential limitations associated with this study including: publication bias, English only search, limited published studies with NER in combination with L or S, adherent populations, and aggregation of multiple populations. Conclusion: The results of the analysis suggest that greater risk reductions in CVEs occur with combination therapies, especially those including niacin extended-release (NER). Up to an 83 risk reduction was estimated for the highest doses of NER and simvastatin (NER/S).

KW - Cardiovascular events

KW - Cholesterol

KW - Dyslipidemia

KW - Lipid-lowering therapy

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=74549183520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549183520&partnerID=8YFLogxK

U2 - 10.1185/03007990903484802

DO - 10.1185/03007990903484802

M3 - Article

C2 - 19995326

AN - SCOPUS:74549183520

VL - 26

SP - 365

EP - 375

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 2

ER -